Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
Tenaya Therapeutics (NASDAQ: TNYA) will present at the Leerink Partners Global Healthcare Conference in Miami from March 9-11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tenaya Therapeutics (NASDAQ: TNYA) will present at the Leerink Partners Global Healthcare Conference in Miami from March 9-11, 2026. CEO Faraz Ali will join a fireside chat on March 9, 2026 at 1:00 pm ET. A live webcast will stream via the company Investors site, with an archived replay available for approximately 30 days.
Details
News Market Reaction – TNYA
On Mar 3, the first trading day after this news, TNYA closed 3.51% below the previous close.
Data tracked by StockTitan Argus for the Mar 3 session.
Key Figures
- Conference dates
- March 9–11, 2026
- Leerink Partners Global Healthcare Conference
- Fireside chat date
- March 9, 2026
- CEO participation at conference
- Fireside chat time
- 1:00 pm ET
- Scheduled presentation time
- Webcast archive duration
- 30 days
- Replay availability after conference
Historical Context
-
Outlined 2026 priorities, clinical milestones and funding runway through mid-2027.
-
Priced public offering of 50M units at $1.20 with attached warrants.
-
Announced intent to offer stock and warrant units under existing Form S-3.
-
FDA removed clinical hold on MyPEAK-1 trial of TN-201 after protocol changes.
-
Reported positive interim RIDGE-1 TN-401 data with PVC reductions and tolerability.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Company management will be participating in the upcoming Leerink Partners Global Healthcare Conference taking place from March 9-11, 2026 in Miami, Florida. Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat on Monday, March 9, 2026, at 1:00 pm ET.
The live webcast of the fireside chat may be accessed from the Investors section of Tenaya’s website. An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.